Daewon Pharmaceutical said Wednesday it has launched a new cold-medicine line, the Daewoncol Soft Capsule series, with different formulations tailored to symptoms.
The series has three products: Daewoncol Cold (multi-symptom), Daewoncol Cough (cough cold) and Daewoncol Nose (nasal cold), allowing consumers to choose based on symptoms.
Daewon said the key difference is the dosage form: soft capsules filled with liquid ingredients, which it said can be absorbed faster than tablets and offer higher bioavailability for quicker effects.
The company said it also boosted ingredient content, including 250 mg of acetaminophen per capsule, the maximum allowed under revised drug rules. Adults taking two capsules per dose would get 500 mg, which Daewon said helps relieve headaches, fever and muscle aches.
Daewoncol Cold is designed to ease multiple symptoms such as runny nose, cough and fever. Daewoncol Cough strengthens ingredients aimed at throat-related symptoms including cough, phlegm and sore throat. Daewoncol Nose focuses on runny nose, congestion and sneezing.
SK Biopharm’s U.S. unit, SK Life Science, said Wednesday it held its “2026 National Sales Meeting” from Feb. 9-12 in Orlando, Florida.
The company said the event has been held annually since the 2020 launch of cenobamate, sold in the United States as Xcopri, and marked its seventh meeting this year. About 290 employees from South Korea and overseas attended, including CEO Lee Dong Hoon, to discuss strategies to strengthen sales. This year’s slogan was “We Will,” emphasizing voluntary execution and proactive growth, the company said.
SK Biopharm said the central message was “One Team,” highlighting cooperation between headquarters and the U.S. unit based on each side’s expertise, as it seeks to strengthen the cenobamate business and expand into oncology. The company said cenobamate posted record U.S. sales of 630.3 billion won in 2025, up about 44% from a year earlier.
Samsung Bioepis said Wednesday it has signed a U.S. settlement and license agreement with Regeneron and Bayer, the makers of the original drug, covering the 2 mg formulation of its ophthalmology biosimilar Opuviz (aflibercept).
Under the agreement, Samsung Bioepis said it will be able to launch Opuviz in the United States in January 2027. The company said it completed global patent settlements for the Eylea biosimilar in January, following agreements in Europe and other markets.
Opuviz was approved by the U.S. Food and Drug Administration in 2024. In South Korea, it was approved under the brand name Apilibu and launched in May 2024. The original drug, Eylea, treats eye diseases including wet age-related macular degeneration. Samsung Bioepis said Eylea had global sales of about 14 trillion won in 2024, including about 9 trillion won in the United States.
Jaseng Korean Medicine Hospital said Wednesday it held Lunar New Year events for inpatients and outpatients at five hospitals nationwide: Incheon, Daejeon, Busan, Cheongju and Changwon.
The Incheon hospital ran traditional games such as biseokchigi for inpatients, with medical staff joining in, and offered winter snacks and prizes.
The Daejeon hospital held games with added penalties and missions. The Busan hospital ran traditional folk-game programs with staff participation, while the Cheongju hospital held a capsule-draw event and provided holiday gifts.
The Changwon hospital said it plans to hold events and hands-on programs for outpatients from Feb. 13-16.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.